What is the Optimal Dosage of Aspirin to Prevent Preeclampsia?
BACKGROUND AND PURPOSE:
There is good evidence that aspirin prevents preeclampsia in women at risk, but there is no agreement on the actual dose
In the US, tablets are only available in 81mg and 325mg tablets, while the ASPRE study used 150mg dose
Seidler et al. (AJOG 2018) evaluated optimal aspirin dosing for preeclampsia prevention
Individual participant data (IPD) from a large meta-analyses of preeclampsia prevention was analyzed and compared to ASPRE findings
Preeclampsia with PTB <37 weeks gestation
22 previous RCTs, totaling 30,532 women were included
Preeclampsia was reduced with aspirin dose ≤ 81 mg relative to placebo
Pooled relative risk (RR) 0.92; 95% CI 0.85 – 0.99
Greater risk reduction was seen at doses of >81 mg relative to placebo
Pooled RR, 0.74; 95% CI, 0.60 – 0.92
Similar to results from the ASPRE trial (RR 0.72)
For preeclampsia with PTB, a similar pattern was seen
81 mg: IPD pooled RR, 0.86; 95% CI, 0.75-0.98
>81 mg: IPD pooled RR, 0.75; 95% CI 0.54-1.04
Less effect than seen in ASPRE trial (RR, 0.38)
Adjusting for confounding variables did not alter results
Among the pooled RCTs, preeclampsia and preeclampsia with PTB declined with increasing aspirin doses, but with overlapping confidence intervals
In pooled RCTs that used IPD, the lowest predicted rate of preeclampsia with PTB (1.6%) was observed at a daily dose of 100 mg, the same rate as in the ASPRE trial (1.6%)
There is a dose-response effect of aspirin on prevention of preeclampsia and preeclampsia with PTB up to 150 mg daily
The authors suggest that a future RCT to compare higher doses such as 150 mg or 162 (double the 81mg tablet) vs 81 mg dose is required and “could benefit millions of pregnant women and their fetuses worldwide at a very low cost and risk”
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan